Is APLIF or RYLD a better dividend investment in 2026?

APLIF currently yields 18181.82% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: APLIF offers higher current income.

What is the dividend yield difference between APLIF and RYLD?

APLIF has a forward dividend yield of 18181.82% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 18169.68 percentage points.

Home › Compare › APLIF vs RYLD

APLIF vs RYLD: Dividend Comparison 2026

APLIF yields 18181.82% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 APLIF wins by $20382968138483965952.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

APLIF

● Live price

18181.82%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20382968138483965952.00M

Annual income

$20,164,798,479,641,134,000,000,000.00

Full APLIF calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — APLIF vs RYLD

📍 APLIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	APLIF	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, APLIF + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

APLIF pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APLIF

Annual income on $10K today (after 15% tax)

$1,545,454.55/yr

After 10yr DRIP, annual income (after tax)

$17,140,078,707,694,964,000,000,000.00/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, APLIF beats the other by $17,140,078,707,694,964,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APLIF + RYLD for your $10,000?

APLIF: 50%RYLD: 50%

100% RYLD50/50100% APLIF

Portfolio after 10yr

$10191484069241982976.00M

Annual income

$10,082,399,239,820,567,000,000,000.00/yr

Blended yield

98.93%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APLIF buys

RYLD buys

No recent congressional trades found for APLIF or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAPLIFRYLD

Forward yield	18181.82% ✓	12.14%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$20382968138483965952.00M ✓	$44.5K
Annual income after 10y	$20,164,798,479,641,134,000,000,000.00 ✓	$2,587.35
Total dividends collected	$20368560651224936448.00M ✓	$18.8K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: APLIF vs RYLD ($10,000, DRIP)

Year	APLIF Portfolio	APLIF Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$1,828,882	$1,818,181.82	$11,914	$1,213.65	+$1.82M → APLIF
2	$312,726,966	$310,770,062.56	$14,099	$1,351.30	+$312.71M → APLIF
3	$49,997,862,140	$49,663,244,286.24	$16,580	$1,494.55	+$49997.85M → APLIF
4	$7,474,070,205,933	$7,420,572,493,443.65	$19,384	$1,642.61	+$7474070.19M → APLIF
5	$1,044,712,232,322,833	$1,036,714,977,202,484.10	$22,535	$1,794.70	+$1044712232.30M → APLIF
6	$136,547,911,758,351,100	$135,430,069,669,765,680.00	$26,063	$1,950.00	+$136547911758.33M → APLIF
7	$16,689,313,388,956,088,000	$16,543,207,123,374,653,000.00	$29,995	$2,107.69	+$16689313388956.06M → APLIF
8	$1,907,542,220,817,720,100,000	$1,889,684,655,491,537,200,000.00	$34,361	$2,266.99	+$1907542220817720.25M → APLIF
9	$203,896,877,423,206,970,000,000	$201,855,807,246,932,000,000,000.00	$39,194	$2,427.12	+$203896877423206976.00M → APLIF
10	$20,382,968,138,483,967,000,000,000	$20,164,798,479,641,134,000,000,000.00	$44,525	$2,587.35	+$20382968138483965952.00M → APLIF

APLIF vs RYLD: Complete Analysis 2026

APLIF — Stock

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Full APLIF Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this APLIF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APLIF vs SCHD APLIF vs JEPI APLIF vs O APLIF vs KO APLIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.